Advanced NSCLC Clinical Trials

8 recruiting

Advanced NSCLC Trials at a Glance

11 actively recruiting trials for advanced nsclc are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Nanchang, Shanghai, and Luoyang. Lead sponsors running advanced nsclc studies include The First Affiliated Hospital of Nanchang University, National Cancer Institute (NCI), and Mirati Therapeutics Inc..

Browse advanced nsclc trials by phase

Treatments under study

About Advanced NSCLC Clinical Trials

Looking for clinical trials for Advanced NSCLC? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced NSCLC trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced NSCLC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Squamous Cell CarcinomaAdvanced Non-Small Cell Lung CancerAdvanced NSCLC+2 more
National Cancer Institute (NCI)85 enrolled1 locationNCT02133196
Recruiting
Phase 2

Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

Advanced NSCLC
Shanghai Junshi Bioscience Co., Ltd.66 enrolled18 locationsNCT06924606
Recruiting
Phase 2

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients

First-line Advanced NSCLC Patients
Shenyang Sunshine Pharmaceutical Co., LTD.240 enrolled1 locationNCT07171606
Recruiting
Phase 2

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Metastatic Lung CancerAdvanced NSCLC
Mirati Therapeutics Inc.90 enrolled166 locationsNCT05609578
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor

Advanced NSCLCAdvanced Endometrial Cancer
Huabo Biopharm Co., Ltd.282 enrolled14 locationsNCT06758557
Recruiting
Not Applicable

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

Advanced NSCLC
The First Affiliated Hospital of Nanchang University10 enrolled2 locationsNCT06752057
Recruiting
Not Applicable

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

Advanced NSCLC
The First Affiliated Hospital of Nanchang University10 enrolled2 locationsNCT06752044
Recruiting
Phase 2

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

Advanced NSCLC
The First Affiliated Hospital of Nanchang University10 enrolled2 locationsNCT06751849
Recruiting
Phase 2

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

Advanced NSCLC
The First Affiliated Hospital of Nanchang University10 enrolled2 locationsNCT06751901
Recruiting
Phase 2

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

HER2 Insertion Mutation Positive Advanced NSCLC
Yongchang Zhang30 enrolled1 locationNCT04144569
Recruiting
Phase 2

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

First-line Advanced NSCLC Patients
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.235 enrolled1 locationNCT06412471